November 29, 2022
Article
Approval of the treatment was based on the placebo-controlled phase 3 ARASENS trial, which showed that adding darolutamide to standard ADT and docetaxel boosted overall survival versus ADT/docetaxel alone in patients with metastatic hormone-sensitive prostate cancer.
November 28, 2022
Video
Gary Ulaner, MD, PhD, FACNM provides practical advice for radiologists who are generating PSMA-PET imaging reports, as well as for the urologists who are interpreting PSMA-PET results.
Shared insight from the panel on how they typically select radiotracers when ordering PSMA-PET scans in their clinical practice.
November 22, 2022
“To our knowledge, this study represents the first time a significant association has been demonstrated between concurrent and adjuvant ADT sequencing and overall survival rates among prostate cancer patients," says Amar Kishan, MD.
November 21, 2022
The new data are from a randomized, double-blind, parallel, placebo-controlled phase 3 trial that enrolled patients experiencing ED after receiving a bilateral, nerve-sparing radical prostatectomy.
Citing recent guidelines recommendations, urologists share how they approach sequencing of conventional and PSMA-PET imaging for patients with prostate cancer, and discuss how use of each modality might affect subsequent patient management and treatment decisions.
Urologist Ashley Ross, MD, PhD leads a discussion of the benefits and limitations of PSMA-PET in patients with prostate cancer, as compared to older imaging modalities.
November 17, 2022
Silver also outlines an example of a patient who he would treat with high-intensity focused ultrasound.
November 14, 2022
The application for approval in the European Union is based on findings from the pivotal phase 3 PROpel trial.
Radiologist Gary Ulaner, MD, PhD, FACNM provides a comprehensive discussion on the FDA-approved PSMA radiotracer options that are available for use as part of PSMA-PET imaging.
